Related references
Note: Only part of the references are listed.Olaparib: a promising PARP inhibitor in ovarian cancer therapy
Ying Chen et al.
ARCHIVES OF GYNECOLOGY AND OBSTETRICS (2013)
Synergistic Effect of Olaparib with Combination of Cisplatin on PTEN-Deficient Lung Cancer Cells
Daisuke Minami et al.
MOLECULAR CANCER RESEARCH (2013)
RAD51C-Deficient Cancer Cells Are Highly Sensitive to the PARP Inhibitor Olaparib
Ahrum Min et al.
MOLECULAR CANCER THERAPEUTICS (2013)
PARP Inhibition Sensitizes to Low Dose-Rate Radiation TMPRSS2-ERG Fusion Gene-Expressing and PTEN-Deficient Prostate Cancer Cells
Payel Chatterjee et al.
PLOS ONE (2013)
Differential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells
Hsiao-Ching Chuang et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Cancer Statistics, 2012
Rebecca Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2012)
PTEN Deletion in Prostate Cancer Cells Does Not Associate with Loss of RAD51 Function: Implications for Radiotherapy and Chemotherapy
Michael Fraser et al.
CLINICAL CANCER RESEARCH (2012)
Genome-Wide Single Nucleotide Polymorphism Arrays as a Diagnostic Tool in Patients With Synchronous Endometrial and Ovarian Cancer
Yuji Ikeda et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2012)
Genotype-Dependent Efficacy of a Dual PI3K/mTOR Inhibitor, NVP-BEZ235, and an mTOR Inhibitor, RAD001, in Endometrial Carcinomas
Keiko Shoji et al.
PLOS ONE (2012)
Multifunctional transcription factor TFII-I is an activator of BRCA1 function
M. Tanikawa et al.
BRITISH JOURNAL OF CANCER (2011)
Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations
Konstantin J. Dedes et al.
CELL CYCLE (2011)
Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer
Martin D. Forster et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2011)
PARP Inhibitors in BRCA Gene-Mutated Ovarian Cancer and Beyond
Susana Banerjee et al.
CURRENT ONCOLOGY REPORTS (2011)
PTEN Loss Compromises Homologous Recombination Repair in Astrocytes: Implications for Glioblastoma Therapy with Temozolomide or Poly(ADP-Ribose) Polymerase Inhibitors
Brian McEllin et al.
CANCER RESEARCH (2010)
ATM Deficiency Sensitizes Mantle Cell Lymphoma Cells to Poly(ADP-Ribose) Polymerase-1 Inhibitors
Chris T. Williamson et al.
MOLECULAR CANCER THERAPEUTICS (2010)
PTEN Deficiency in Endometrioid Endometrial Adenocarcinomas Predicts Sensitivity to PARP Inhibitors
Konstantin J. Dedes et al.
SCIENCE TRANSLATIONAL MEDICINE (2010)
The oncogenic mutation in the pleckstrin homology domain of AKT1 in endometrial carcinomas
K. Shoji et al.
BRITISH JOURNAL OF CANCER (2009)
PARP is activated at stalled forks to mediate Mre11-dependent replication restart and recombination
Helen E. Bryant et al.
EMBO JOURNAL (2009)
Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors
Ana M. Mendes-Pereira et al.
EMBO MOLECULAR MEDICINE (2009)
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers.
Peter C. Fong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Mechanism of eukaryotic homologous recombination
Joseph San Filippo et al.
ANNUAL REVIEW OF BIOCHEMISTRY (2008)
PIK3CA cooperates with other phosphatidylinositol 3′-kinase pathway mutations to effect oncogenic transformation
Katsutoshi Oda et al.
CANCER RESEARCH (2008)
4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: A Novel Bioavailable Inhibitor of Poly(ADP-ribose) Polymerase-1
Keith A. Menear et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
Essential role for nuclear PTEN in maintaining chromosomal integrity
Wen Hong Shen et al.
CELL (2007)
Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition
Nuala McCabe et al.
CANCER RESEARCH (2006)
High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma
K Oda et al.
CANCER RESEARCH (2005)
PTEN loss inhibits CHK1 to cause double stranded-DNA breaks in cells
J Puc et al.
CELL CYCLE (2005)
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
H Farmer et al.
NATURE (2005)
Lack of PTEN sequesters CHK1 and initiates genetic instability
J Puc et al.
CANCER CELL (2005)
Ablation of PARP-1 does not interfere with the repair of DNA double-strand breaks, but compromises the reactivation of stalled replication forks
YG Yang et al.
ONCOGENE (2004)
Rad51 recombinase and recombination mediators
P Sung et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Analysis of microsatellite instability and loss of heterozygosity in uterine endometrial adenocarcinoma
T Toda et al.
CANCER GENETICS AND CYTOGENETICS (2001)
Share Paper
